Non-surgical treatment of chondrosarcoma: Current concepts and future perspectives

Bone Cancer

Volumn , Issue , 2010, Pages 375-383

  Staals, Eric L ^a   Palmerini, Emanuela ^b   Ferrari, Stefano ^b   Mercuri, Mario ^a  

^a Istituti Ortopedici Rizzoli   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80052657175     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374895-9.00031-1     Document Type: Chapter

References (113)

1. Unni K.K. Dahlin's Bone Tumors: General Aspects and Data on 11,087 Cases 1996, Lippincott-Raven Publishers, Philadelphia, pp. 71-108. 5th edn.
2. Campanacci M. Bone and Soft Tissue Tumors 1999, Springer-Verlag, Wien, New York, pp. 283-379. 2nd edn.
3. Bertoni F., Bacchini P., Hogendoorn P.C.W. Chondrosarcoma. World Health Organisation Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone 2002, 247-251. IARC Press, Lyon. C.D.M. Fletcher, K.K. Unni, F. Mertens (Eds.).
4. Björnsson J., McLeod R.A., Unni K.K., et al. Primary chondrosarcoma of long bones and limb girdles. Cancer 1998, 83(10):2105-2119.
5. Gitelis S., Bertoni F., Picci P., et al. Chondrosarcoma of bone. The experience at the Istituto Ortopedico Rizzoli. J Bone Joint Surg Am 1981, 63(8):1248-1257.
6. Sandberg A.A. Genetics of chondrosarcoma and related Tumors. Curr Opin Oncol 2004, 16(4):342-354.
7. Tallini G., Dorfman H., Brys P., et al. Correlation between clinicopathological features and karyotype in 100 cartilaginous and chordoid tumours. A report from the Chromosomes and Morphology (CHAMP) Collaborative Study Group. J Pathol 2002, 196(2):194-203.
8. Rozeman L.B., Hogendoorn P.C., Bovée J.V. Diagnosis and prognosis of chondrosarcoma of bone. Expert Rev Mol Diagn 2002, 2(5):461-472.
9. Bovée J.V., Cleton-Jansen A.M., Kuipers-Dijkshoorn N.J., et al. Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma. Genes Chromosomes Cancer 1999, 26(3):237-246.
10. Larramendy M.L., Tarkkanen M., Valle J., et al. Gains, losses, and amplifications of DNA sequences evaluated by comparative genomic hybridization in chondrosarcomas. Am J Pathol 1997, 150(2):685-691.
11. Bovée J.V., Cleton-Jansen A.M., Wuyts W., et al. EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas. Am J Hum Genet 1999, 65(3):689-698.
12. Bovée J.V., Cleton-Jansen A.M., Taminiau A.H., et al. Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol 2005, 6(8):599-607.
13. Evans H.L., Ayala A.G., Romsdahl M.M. Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. Cancer 1977, 40(2):818-831.
14. Van der Geest I.C., de Valk M.H., de Rooy J.W., et al. Oncological and functional results of cryosurgical therapy of enchondromas and chondrosarcomas grade 1. J Surg Oncol 2008, 98(6):421-426.
15. Leerapun T., Hugate R.R., Inwards C.Y., et al. Surgical management of conventional grade I chondrosarcoma of long bones. Clin Orthop Relat Res 2007, 463:166-172.
16. Ahlmann E.R., Menendez L.R., Fedenko A.N., et al. Influence of cryosurgery on treatment outcome of low-grade chondrosarcoma. Clin Orthop Relat Res 2006, 451:201-207.
17. A. Streitbürger, H. Ahrens, M. Balke, et al. Grade I chondrosarcoma of bone: the Münster experience. J Cancer Res Clin Oncol Oct 15 (2008) [Epub ahead of print].
18. Lee F.Y., Mankin H.J., Fondren G., et al. Chondrosarcoma of bone: an assessment of outcome. J Bone Joint Surg Am 1999, 81(3):326-338.
19. Lichtenstein L., Bernstein D. Unusual benign and malignant chondroid tumors of bone: a survey of some mesenchymal cartilage tumors and malignant chondroblastic tumors, including a few multicentric ones, as well as many atypical benign chondroblastomas and chondromyxoid fibromas. Cancer 1959, 12:1142-1157.
20. Nakashima Y., Unni K.K., Shives T.C., et al. Mesenchymal chondrosarcoma of bone and soft tissue. A review of 111 cases. Cancer 1986, 57(12):2444-2453.
21. Naumann S., Krallman P.A., Unni K.K., et al. Translocation der(13;21)(q10;q10) in skeletal and extraskeletal mesenchymal chondrosarcoma. Mod Pathol 2002, 15:572-576.
22. Park Y.K., Park H.R., Chi S.G., et al. Overexpression of p53 and absent genetic mutation in clear cell chondrosarcoma. Int J Oncol 2001, 19:353-357.
23. Huvos A.G., Rosen G., Dabska M., et al. Mesenchymal chondrosarcoma. A clinicopathologic analysis of 35 patients with emphasis on treatment. Cancer 1983, 51(7):1230-1237.
24. Cesari M., Bertoni F., Bacchini P., et al. Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution. Tumori 2007, 93(5):423-427.
25. Dahlin D.C., Beabout J.W. Dedifferentiation of low-grade chondrosarcomas. Cancer 1971, 28:461-466.
26. Frassica F.J., Unni K.K., Beabout J.W., et al. Dedifferentiated chondrosarcoma. A report of the clinicopathological features and treatment of seventy-eight cases. J Bone Joint Surg Am 1986, 68(8):1197-1205.
27. Capanna R., Bertoni F., Bettelli G., et al. Dedifferentiated chondrosarcoma. J Bone Joint Surg Am 1988, 70(1):60-69.
28. Mercuri M., Picci P., Campanacci L., et al. Dedifferentiated chondrosarcoma. Skeletal Radiol 1995, 24(6):409-416.
29. Mitchell A.D., Ayoub K., Mangham D.C., et al. Experience in the treatment of dedifferentiated chondrosarcoma. J Bone Joint Surg Br 2000, 82(1):55-61.
30. Dickey I.D., Rose P.S., Fuchs B., et al. Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes. J Bone Joint Surg Am 2004, 86-A(11):2412-2418.
31. Bruns J., Fiedler W., Werner M., et al. Dedifferentiated chondrosarcoma-a fatal disease. J Cancer Res Clin Oncol 2005, 131(6):333-339.
32. Staals E.L., Bacchini P., Bertoni F. Dedifferentiated central chondrosarcoma. Cancer 2006, 106(12):2682-2691.
33. Staals E.L., Bacchini P., Mercuri M., et al. Dedifferentiated chondrosarcomas arising in preexisting osteochondromas. J Bone Joint Surg Am 2007, 89(5):987-993.
34. Grimer R.J., Gosheger G., Taminiau A., et al. Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group. Eur J Cancer 2007, 43(14):2060-2065.
35. Bovée J.V., Cleton-Jansen A.M., Rosenberg C., et al. Molecular genetic characterization of both components of a dedifferentiated chondrosarcoma, with implications for its histogenesis. J Pathol 1999, 189(4):454-462.
36. Röpke M., Boltze C., Neumann H.W., et al. Genetic and epigenetic alterations in tumor progression in a dedifferentiated chondrosarcoma. Pathol Res Pract 2003, 199:437-444.
37. Grote H.J., Schneider-Stock R., Neumann W., et al. Mutation of p53 with loss of heterozygosity in the osteosarcomatous component of a dedifferentiated chondrosarcoma. Virchows Arch 2000, 436:494-497.
38. Bramwell V.H., Steward W.P., Nooij M., et al. Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: a European Osteosarcoma Intergroup study. J Clin Oncol 1999, 17:3260-3269.
39. Grimer R.J., Cannon S.R., Taminiau A.M., et al. Osteosarcoma over the age of forty. Eur J Cancer 2003, 39:157-163.
40. Aigner T., Unni K.K. Is dedifferentiated chondrosarcoma a 'de-differentiated' chondrosarcoma?. J Pathol 1999, 189:445-447.
41. ISG, SSG, COSS (2003). A European treatment protocol for bone sarcoma in patients older than 40 years. Scandinavian Sarcoma Group and Oncologic Center, Lund, Sweden,. http://www.ocsyd.se/VP-verksamhet/Hud%20mjukdel%20skelett/Euroboss1.pdf.
42. Unni K.K., Dahlin D.C., Beabout J.W., et al. Chondrosarcoma: clear-cell variant. A report of sixteen cases. J Bone Joint Surg Am 1976, 58:676-683.
43. Nishio J., Reith J.D., Ogose A., et al. Cytogenetic findings in clear cell chondrosarcoma. Cancer Genet Cytogenet 2005, 162:74-77.
44. Bjornsson J., Unni K.K., Dahlin D.C., et al. Clear cell chondrosarcoma of bone. Observations in 47 cases. Am J Surg Pathol 1984, 8:223-230.
45. Donati D., Yin J.Q., Colangeli M., et al. Clear cell chondrosarcoma of bone: long time follow-up of 18 cases. Arch Orthop Trauma Surg 2008, 128:137-142.
46. Kalil R.K., Inwards C.Y., Unni K.K., et al. Dedifferentiated clear cell chondrosarcoma. Am J Surg Pathol 2000, 24:1079-1086.
47. Terek R.M., Schwartz G.K., Devaney K., et al. Chemotherapy and P-glycoprotein expression in chondrosarcoma. J Orthop Res 1998, 16(5):585-590.
48. Wyman J.J., Hornstein A.M., Meitner P.A., et al. Multidrug resistance-1 and p-glycoprotein in human chondrosarcoma cell lines: expression correlates with decreased intracellular doxorubicin and in vitro chemoresistance. J Orthop Res 1999, 17(6):935-940.
49. Schwarzbach M.H., Eisold S., Burguete T., et al. Sensitization of sarcoma cells to doxorubicin treatment by concomitant wild-type adeno-associated virus type 2 (AAV-2) infection. Int J Oncol 2002, 20(6):1211-1218.
50. Antman K.H., Montella D., Rosenbaum C., et al. Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. Cancer Treat Rep 1985, 69(5):499-504.
51. La Rocca R.V., Morgan K.W., Paris K., et al. Recurrent chondrosarcoma of the cranial base: a durable response to ifosfamide-doxorubicin chemotherapy. J Neuro Oncol 1999, 41(3):281-283.
52. Debruyne P.R., Dumez H., Demey W., et al. Recurrent low- to intermediate-grade chondrosarcoma of the thumb with lung metastases: an objective response to trofosfamide. Onkologie 2007, 30(4):201-204.
53. Southwest Oncology Group. Pemetrexed disodium in treating patients with recurrent and unresectable or metastatic chondrosarcoma. December 2007. http://www.clinicaltrials.gov/ct2/show/NCT00107419.
54. Children's Oncology Group (NCI). Gemcitabine and docetaxel in treating patients with recurrent osteosarcoma or Ewing's sarcoma or unresectable or locally recurrent chondrosarcoma. January 2008. http://www.clinicaltrials.gov/ct2/show/NCT00073983.
55. Terek R.M. Recent advances in the basic science of chondrosarcoma. Orthop Clin North Am 2006, 37(1):9-14.
56. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347(7):472-480.
57. Kantarjian H., Sawyers C., Hochhaus A., et al. International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002, 346(9):645-652.
58. Sjöblom T., Shimizu A., O'Brien K.P., et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001, 61:5778-5783.
59. Lagonigro M.S., Tamborini E., Negri T., et al. PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma. J Pathol 2006, 208(5):615-623.
60. Sulzbacher I., Birner P., Trieb K., et al. Platelet-derived growth factor-βlpha receptor expression supports the growth of conventional chondrosarcoma and is associated with adverse outcome. Am J Surg Pathol 2001, 25(12):1520-1527.
61. Deininger M.W., Druker B.J. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 2003, 55(3):401-423.
62. Italian Sarcoma Group. Studio di fase II sull'utilizzo di imatinib mesilato nel trattamento del tumore Desmoide e del condrosarcoma. February 2008. http://www.oss-sper-clin.agenziafarmaco.it/.
63. Sarcoma Alliance for Research through Collaboration (SARC). Trial of Dasatinib in Advanced Sarcomas. January 2008. http://www.clinicaltrials.gov/ct2/show/NCT00464620.
64. Hennessy B.T., Lu Y., Poradosu E., et al. Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res 2007, 13(24):7421-7431.
65. Sarcoma Alliance for Research through Collaboration (SARC). A trial of Perifosine in patients with chemo-insensitive sarcomas. January 2008. http://www.clinicaltrials.gov/ct2/show/NCT00401388.
66. Buchsbaum D.J., Forero-Torres A., LoBuglio A.F. TRAIL-receptor antibodies as a potential cancer treatment. Future Oncol 2007, 3(4):405-409.
67. Huang Y., Sheikh M.S. TRAIL death receptors and cancer therapeutics. Toxicol Appl Pharmacol 2007, 224(3):284-289.
68. Genentech. A study of Apomab in patients with advanced chondrosarcoma. December 2007. http://www.clinicaltrials.gov/ct2/show/NCT00543712.
69. S. Chawla, G. Demetri, & J. Desai, et al. Initial results of a phase II study of the safety and efficacy of the Apomab DR5 agonist antibody in advanced chondrosarcoma and synovial sarcoma patients. CTOS Annual Meeting 2008, Abstract 35010.
70. van der Eerden B.C., Karperien M., Gevers E.F., et al. Expression of Indian hedgehog, parathyroid hormone-related protein, and their receptors in the postnatal growth plate of the rat: evidence for a locally acting growth restraining feedback loop after birth. J Bone Miner Res 2000, 15(6):1045-1055.
71. Hopyan S., Gokgoz N., Poon R., et al. A mutant PTH/PTHrP type I receptor in enchondromatosis. Nat Genet 2002, 30(3):306-310.
72. Tiet T.D., Hopyan S., Nadesan P., et al. Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation. Am J Pathol 2006, 168(1):321-330.
73. Morrison C., Radmacher M., Mohammed N., et al. MYC amplification and polysomy 8 in chondrosarcoma: array comparative genomic hybridization, fluorescent in situ hybridization, and association with outcome. J Clin Oncol 2005, 23(36):9369-9376.
74. Wunder J.S., Nielsen T.O., Maki R.G., et al. Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol 2007, 8(6):513-524.
75. Kiselyov A.S. Targeting the hedgehog signaling pathway with small molecules. Anticancer Agents Med Chem 2006, 6(5):445-449.
76. Rozeman L.B., Hameetman L., Cleton-Jansen A.M., et al. Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas. J Pathol 2005, 205(4):476-482.
77. Bovée J.V., Van Den Broek L.J., Cleton-Jansen A.M., et al. Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma. Lab Invest 2000, 80(12):1925-1934.
78. Amling M., Pösl M., Hentz M.W., et al. PTHrP and Bcl-2: essential regulatory molecules in chondrocyte differentiation and chondrogenic tumors. Verh Dtsch Ges Pathol 1998, 82:160-169.
79. Kunisada T., Moseley J.M., Slavin J.L., et al. Co-expression of parathyroid hormone-related protein (PTHrP) and PTH/PTHrP receptor in cartilaginous tumours: a marker for malignancy?. Pathology 2002, 34(2):133-137.
80. Pateder D.B., Gish M.W., O'Keefe R.J., et al. Parathyroid hormone-related peptide expression in cartilaginous tumors. Clin Orthop Relat Res 2002, 403:198-204.
81. Hameetman L., Kok P., Eilers P.H., et al. The use of Bcl-2 and PTHLH immunohistochemistry in the diagnosis of peripheral chondrosarcoma in a clinicopathological setting. Virchows Arch 2005, 446(4):430-437.
82. Kim R., Emi M., Tanabe K., et al. Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy. Cancer 2004, 101(11):2491-2502.
83. Miyaji T., Nakase T., Onuma E., et al. Monoclonal antibody to parathyroid hormone related protein induces differentiation and apoptosis of chondrosarcoma cells. Cancer Lett 2003, 199(2):147-155.
84. Geirnaerdt M.J., Hogendoorn P.C., Bloem J.L., et al. Cartilaginous tumors: fast contrast-enhanced MR imaging. Radiology 2000, 214(2):539-546.
85. Ayala G., Liu C., Nicosia R., et al. Microvasculature and VEGF expression in cartilaginous tumors. Hum Pathol 2000, 31(3):341-346.
86. Kalinski T., Krueger S., Sel S., et al. Differential expression of VEGF-A and angiopoietins in cartilage tumors and regulation by interleukin-1beta. Cancer 2006, 106(9):2028-2038.
87. Morioka H., Weissbach L., Vogel T., et al. Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis. Clin Cancer Res 2003, 9(3):1211-1217.
88. Levine A.M., Tulpule A., Quinn D.I., et al. Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J Clin Oncol 2006, 24(11):1712-1719.
89. Jiang X., Dutton C.M., Qi W., et al. Inhibition of MMP-1 expression by antisense RNA decreases invasiveness of human chondrosarcoma. J Orthop Res 2003, 21(6):1063-1070.
90. Sutton K.M., Wright M., Fondren G., et al. Cyclooxygenase-2 expression in chondrosarcoma. Oncology 2004, 66(4):275-280.
91. Gouin F., Ory B., Rédini F., et al. Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival. Int J Cancer 2006, 119(5):980-984.
92. Kubo T., Shimose S., Matsuo T., et al. Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells. J Orthop Res 2008, 24(6):1138-1144.
93. Lai T.J., Hsu S.F., Li T.M., et al. Alendronate inhibits cell invasion and MMP-2 secretion in human chondrosarcoma cell line. Acta Pharmacol Sin 2007, 28(8):1231-1235.
94. Villar-Garea A., Esteller M. Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int J Cancer 2004, 112(2):171-178.
95. Sakimura R., Tanaka K., Nakatani F., et al. Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors. Int J Cancer 2005, 116(5):784-792.
96. Sakimura R., Tanaka K., Yamamoto S., et al. The effects of histone deacetylase inhibitors on the induction of differentiation in chondrosarcoma cells. Clin Cancer Res 2007, 13(1):275-282.
97. Nilsson O., Marino R., De Luca F., et al. Endocrine regulation of the growth plate. Horm Res 2005, 64(4):157-165.
98. Cleton-Jansen A.M., van Beerendonk H.M., Baelde H.J., et al. Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma. Clin Cancer Res 2005, 11(22):8028-8035.
99. Grifone T.J., Haupt H.M., Podolski V., et al. Immunohistochemical expression of estrogen receptors in chondrosarcomas and enchondromas. Int J Surg Pathol 2008, 16(1):31-37.
100. Fong Y.C., Yang W.H., Hsu S.F., et al. 2-Methoxyestradiol induces apoptosis and cell cycle arrest in human chondrosarcoma cells. J Orthop Res 2007, 25(8):1106-1114.
101. Moussavi-Harami F., Mollano A., Martin J.A., et al. Intrinsic radiation resistance in human chondrosarcoma cells. Biochem Biophys Res Commun 2006, 346(2):379-385.
102. Kim D.W., Seo S.W., Cho S.K., et al. Targeting of cell survival genes using small interfering RNAs (siRNAs) enhances radiosensitivity of Grade II chondrosarcoma cells. J Orthop Res 2007, 25(6):820-828.
103. Rhomberg W., Eiter H., Böhler F., et al. Combined radiotherapy and razoxane in the treatment of chondrosarcomas and chordomas. Anticancer Res 2006, 26(3B):2407-2411.
104. Krochak R., Harwood A.R., Cummings B.J., et al. Results of radical radiation for chondrosarcoma of bone. Radiother Oncol 1983, 1(2):109-115.
105. Muthukumar N., Kondziolka D., Lunsford L.D., et al. Stereotactic radiosurgery for chordoma and chondrosarcoma: further experiences. Int J Radiat Oncol Biol Phys 1998, 41(2):387-392.
106. Hasegawa T., Ishii D., Kida Y., et al. Gamma knife surgery for skull base chordomas and chondrosarcomas. J Neurosurg 2007, 107(4):752-757.
107. Martin J.J., Niranjan A., Kondziolka D., et al. Radiosurgery for chordomas and chondrosarcomas of the skull base. J Neurosurg 2007, 107(4):758-764.
108. McLoughlin G.S., Sciubba D.M., Wolinsky J.P. Chondroma/Chondrosarcoma of the spine. Neurosurg Clin N Am 2008, 19(1):57-63.
109. Mazeron J.J., Noel G., Feuvret L., et al. Clinical complementarities between proton and carbon therapies. Radiother Oncol 2004, 73(Suppl 2):S50-S52.
110. Hug E.B., Slater J.D. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. Neurosurg Clin N Am 2000, 11(4):627-638.
111. M.D. Anderson, Cancer Center. Proton beam therapy for chondrosarcoma. January 2008. http://www.clinicaltrials.gov/ct2/show/NCT00496522.
112. Massachusetts General Hospital. Charged particle RT for chordomas and chondrosarcomas of the base of the skull of cervical spine. January 2008. http://www.clinicaltrials.gov/ct2/show/NCT00592748.
113. Schulz-Ertner D., Nikoghosyan A., Hof H., et al. Carbon ion radiotherapy of skull base chondrosarcomas. Int J Radiat Oncol Biol Phys 2007, 67(1):171-177.